Vanguard Group Inc Caladrius Biosciences, Inc. Transaction History

Vanguard Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.48 - $7.8 $1.27 Million - $20.6 Million	-2,644,608 Closed	0 $0
Q2 2022 Aug 12, 2022	SELL	$0.41 - $0.74 $19,572 - $35,325	-47,737 Reduced 1.77%	2,644,608 $1.4 Million
Q4 2021 Feb 14, 2022	SELL	$0.83 - $1.22 $2,963 - $4,355	-3,570 Reduced 0.13%	2,692,345 $2.27 Million
Q3 2021 Nov 12, 2021	SELL	$1.15 - $1.57 $2,438 - $3,328	-2,120 Reduced 0.08%	2,695,915 $3.29 Million
Q2 2021 Aug 13, 2021	BUY	$1.4 - $1.9 $3.78 Million - $5.13 Million	2,698,035 New	2,698,035 $4.34 Million

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.